Key Points The V007 study enrolled 242 U.S. patients with end-stage kidney disease who needed new vascular access for hemodialysis. At six months, 81.3% of…
Key Points AvMEDICAL will market CyPath Lung through its national sales team and established federal procurement network. The agreement targets VA medical centers and other…
Key Points CareCloud will develop LailaCare, a customized AI-powered platform for KabaFusion’s home infusion and specialty pharmacy operations. The platform is intended to combine referral intake,…
Key Points AL001 data will be presented during a 10-minute oral session on September 29, 2026, at the ISMRM X-Nuclei MR Workshop. The completed Phase…
Key Points InspireMD expects potential FDA decisions in Q4 2026 for the CGuard Prime 80 cmsystem for transcarotid artery revascularization, or TCAR, and its original CGuard carotid artery…
August 17, 2026
Faeth Therapeutics Gains FDA Fast Track Status Ahead of Phase 2 Endometrial Cancer Readout
PIKTOR is designed to inhibit multiple points in a cancer-driving pathway, with topline data expected by year-end. Faeth Therapeutics (Nasdaq: FTH) has received FDA Fast…
Key Points The companies expect the transaction to close in Q4 2026, subject to shareholder, regulatory, court, Nasdaq, and other approvals. Fibrx will be led…
August 17, 2026
Ocular Therapeutix Rises After EyePoint’s Wet AMD Trial Miss Reshapes Competitive Landscape
Key Points EyePoint’s DURAVYU did not meet LUGANO’s primary endpoint of change from baseline in best-corrected visual acuity compared with aflibercept in the full patient…
August 17, 2026
Femasys Bolsters Its Growth Plan With $30 Million Financing as FemBloc and FemaSeed Programs Advance
Key Points Femasys completed a $30 million private placement after June 30, with up to $60 million in potential additional proceeds if related warrants are…
August 14, 2026
Allogene’s ALPHA3 Data and FDA Designations Sharpen the Case for Cema-Cel in Lymphoma
Key Points Allogene Therapeutics reported Q2 2026 results and a business update, highlighted by an interim futility analysis in the pivotal ALPHA3 trial of cema-cel…
Fresh capital follows positive Phase 2 data for ML-007C-MA as drug developers target cognition, negative symptoms and treatment adherence. Schizophrenia remains one of psychiatry’s most…
The planned 800-patient U.S. study will test an oral FASN inhibitor in moderate to severe acne, including approximately 450 adolescents. Sagimet Biosciences (Nasdaq: SGMT) is…